Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Sunshine Biopharma (SBFM) Long-Term Debt Issuances (2016 - 2021)

Sunshine Biopharma filings provide 8 years of Long-Term Debt Issuances readings, the most recent being $1.4 million for Q3 2021.

  • On a quarterly basis, Long-Term Debt Issuances rose 168.39% to $1.4 million in Q3 2021 year-over-year; TTM through Dec 2021 was $5.1 million, a 204.85% increase, with the full-year FY2021 number at $3.3 million, up 98.21% from a year prior.
  • Long-Term Debt Issuances hit $1.4 million in Q3 2021 for Sunshine Biopharma, down from $2.6 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $2.6 million in Q2 2021 to a low of -$370467.0 in Q4 2017.
  • Median Long-Term Debt Issuances over the past 5 years was $202253.5 (2019), compared with a mean of $429048.6.
  • Biggest five-year swings in Long-Term Debt Issuances: tumbled 189.49% in 2018 and later surged 159135.37% in 2020.
  • Sunshine Biopharma's Long-Term Debt Issuances stood at -$370467.0 in 2017, then skyrocketed by 101.83% to $6794.0 in 2018, then surged by 181.5% to $19125.0 in 2019, then soared by 5116.22% to $997603.0 in 2020, then skyrocketed by 40.34% to $1.4 million in 2021.
  • The last three reported values for Long-Term Debt Issuances were $1.4 million (Q3 2021), $2.6 million (Q2 2021), and $1.2 million (Q1 2021) per Business Quant data.